Societal Color Logo and Tagline.png
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
01 févr. 2024 07h00 HE | Societal CDMO, Inc.
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign MAPS was featured on custom-designed cleats worn by Offensive Lineman Jon Feliciano during the San Francisco 49ers vs Philadelphia Eagles game
scilogo.jpg
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
28 nov. 2023 08h25 HE | SciSparc Ltd
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- ...
ihl_logo.png
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
16 nov. 2023 08h30 HE | Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day Eight virtual conference sessions explore psychedelic research for Veterans including trauma support, federal backing, and a pilot study on Ibogaine
logo.png
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
08 nov. 2023 08h11 HE | Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Picture3.jpg
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
06 sept. 2023 09h20 HE | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...